Citi raises Roivant Sciences (ROIV) PT to $35 following positive phase 2 brepocitinib data
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating. The firm cited encouraging Phase 2 data for...
Insider Monkey